Video

Dr. Bekaii-Saab on the Impact of COVID-19 on Telemedicine

Tanios S. Bekaii-Saab, MD, FACP, discusses the impact of the novel coronavirus 2019 on telemedicine.

Tanios S. Bekaii-Saab, MD, FACP, medical oncologist, medical director, Cancer Clinical Research Office, vice chair and section chief, Medical Oncology, Department of Internal Medicine, Mayo Clinic, discusses the impact of the novel coronavirus 2019 (COVID-19) on telemedicine.

COVID-19 has created a pandemic of such magnitude that the majority of the population has never experienced before, explains Bekaii-Saab.

Moreover, COVID-19 raises specific concerns regarding older individuals with comorbidities as they are at an increased risk of dying from the virus, says Bekaii-Saab.

To minimize the number of patients exposed to COVID-19, Mayo Clinic implemented safety measures like telemedicine early on, explains Bekaii-Saab. Though telemedicine was used prior to the outbreak, its role has grown significantly over the course of the pandemic. It is likely that telehealth will retain its role after COVID-19 has subsided, concludes Bekaii-Saab.

Related Videos
Alberto Montero, MD, MBA, CPHQ, clinical director, Breast Cancer Medical Oncology Program, University Hospitals Seidman Cancer Center; associate professor, medicine, Case Western Reserve University School of Medicine
JURCZACK
Adam E. Singer, MD, PhD, health sciences clinical instructor, medicine, division lead, Kidney Cancer, Division of Hematology/Oncology, UCLA Health
Dr Burke on the Assessment of Barriers to Initiating Venetoclax-Based Regimens for CLL
Bradley McGregor, MD,
Ira Zackon, MD
Jacob E. Berchuck, MD
Javier Pinilla, MD, PhD, and Talha Badar, MBBS, MD, highlight key data in CML and ALL presented at the 2024 ASH Annual Meeting.
Javier Pinilla, MD, PhD, and Talha Badar, MBBS, MD, detail factors for selecting a TKI in later lines of therapy in chronic myeloid leukemia.
Javier Pinilla, MD, PhD, and Talha Badar, MBBS, MD, discuss data for ponatinib plus chemotherapy in Ph-positive ALL.